Charles S. Berkman
General Counsel
OmniAb, Inc. (OABI)Equibles does not estimate personal net worth.
Get an email with a short summary when OmniAb, Inc. publishes a filing, an earnings call transcript or a press release.
Get OABI alertsAbout Charles S. Berkman
Charles S. Berkman is recorded as General Counsel at OmniAb, Inc. (OABI) since November 1, 2022. Earlier roles on record: General Counsel at Ligand Pharmaceuticals Inc (LGND) until November 1, 2022. OmniAb, Inc. reported in an 8-K filed November 7, 2022 that Charles S. Berkman was appointed Chief Legal Officer and Secretary, effective November 1, 2022. Ligand Pharmaceuticals Inc reported in an 8-K filed November 4, 2022 that Charles S. Berkman resigned as Senior Vice President, General Counsel and Secretary, effective November 1, 2022. The proxy statement of OmniAb, Inc. reports total compensation of $1,624,425 for Charles S. Berkman in fiscal 2025, including a base salary of $503,528. Disclosed compensation is on record for 9 fiscal years. OmniAb, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at OmniAb, Inc. includes Matthew Foehr (CEO and Board Member), Matthew W. Foehr (CEO and Board Member), John L. Higgins (Chairman and Board Member) and 7 others.
“Matthew W. Foehr was appointed as OmniAb's President and Chief Executive Officer, Kurt A. Gustafson was appointed as OmniAb's Executive Vice President, Finance, and Chief Financial Officer and Charles S. Berkman was appointed as OmniAb's Chief Legal Officer and Secretary.”
“on November 1, 2022, in connection with the Separation, Matthew Foehr and Charles Berkman resigned as Ligand's President and Chief Operating Officer and Senior Vice President, General Counsel and Secretary, respectively.”
Affiliation history
-
Current
2022-11-01–present
-
OmniAb, Inc. (OABI)
Proxy statement
CurrentStart not stated–present
Last confirmed April 29, 2026
-
Start not stated–2022-11-01
-
Start not stated–2022-11-01
Company network
Leadership on record at OmniAb, Inc.
- Matthew Foehr CEO, Board Member
- Matthew W. Foehr CEO, Board Member
- John L. Higgins Chairman, Board Member
- Kurt A. Gustafson CFO
- Kurt Gustafson CFO
- Amechi Nwachuku COO
- Carolyn Bertozzi Board Member
- Carolyn Bertozzi, Ph.D. Board Member
- Carolyn R. Bertozzi Board Member
- Carolyn R. Bertozzi, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | OmniAb, Inc. (OABI) | Chief Legal Officer and Secretary | $503,528 | $1,624,425 |
| 2024 | OmniAb, Inc. (OABI) | Chief Legal Officer and Secretary | $494,479 | $1,690,109 |
| 2023 | OmniAb, Inc. (OABI) | Chief Legal Officer and Secretary | $485,576 | $1,336,498 |
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Former Senior Vice President, General Counsel and Secretary | $396,920 | $2,433,437 |
| 2022 | OmniAb, Inc. (OABI) | Chief Legal Officer and Secretary | $476,393 | $4,080,569 |
| 2021 | Ligand Pharmaceuticals Inc (LGND) | Former Senior Vice President, General Counsel and Secretary | $451,682 | $2,980,948 |
| 2021 | OmniAb, Inc. (OABI) | Chief Legal Officer and Secretary | $451,682 | $2,980,948 |
| 2020 | Ligand Pharmaceuticals Inc (LGND) | Former Senior Vice President, General Counsel and Secretary | $441,917 | $1,944,852 |
| 2019 | Ligand Pharmaceuticals Inc (LGND) | Senior Vice President and General Counsel | $427,620 | $2,027,167 |
| 2018 | Ligand Pharmaceuticals Inc (LGND) | Senior Vice President and General Counsel | $402,500 | $1,743,579 |
| 2017 | Ligand Pharmaceuticals Inc (LGND) | Senior Vice President and General Counsel | $362,812 | $1,498,819 |